Latest ENTX news and sentiment

Seven Fleet funds disclose 4.1% Entera Bio (ENTX) stake and shared voting power

Seven Fleet funds, including Seven Fleet Horizon Master Fund and Seven Fleet Master Fund, along with Brian Liu, have disclosed a collective 4.1% beneficial ownership in Entera Bio (ENTX), amounting to 7,053,898 Ordinary Shares. This stake is reported with shared voting and dispositive power. The filing also notes that Longitude Capital Management and its affiliates may own 4.6% of Entera Bio, and while policies could deem them a group with Seven Fleet, all parties explicitly disclaim such group status.

Entera Bio (ENTX) stake of 12.25M shares reported by TCG Crossover

TCG Crossover Fund III, L.P., TCG Crossover GP III, LLC, and Chen Yu have reported a beneficial ownership of 12,254,901 ordinary shares of Entera Bio Ltd. (ENTX), which constitutes a 7.1% stake in the company. This ownership is based on 172,251,449 ordinary shares outstanding, including shares issued in a private placement that closed on July 28, 2026. The reporting persons have shared voting and dispositive power over these shares.

Vivo Opportunity group (NASDAQ: ENTX) discloses 12.3M-share holding in Entera Bio

Vivo Opportunity group has disclosed a significant stake in Entera Bio (NASDAQ: ENTX) through a Schedule 13G filing. Vivo Opportunity, LLC beneficially owns 11,817,401 Ordinary Shares, representing 6.9% of Entera Bio’s outstanding shares, while Vivo Opportunity Cayman, LLC holds an additional 437,500 shares, or 0.3%. The reported ownership percentages are based on 172,251,411 Ordinary Shares outstanding, which includes 122,961,215 shares issued in a private placement on July 28, 2026.

Entera Bio’s EB613 data selected for plenary poster at ASBMR

Entera Bio Ltd. announced that post-hoc data from its Phase 2 clinical trial of EB613, an oral PTH(1-34) tablet for osteoporosis, has been selected for two presentations at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting. One of these presentations will be a Plenary Poster Presentation, recognizing its high ranking. The data highlights enhanced anabolic effects of EB613 in postmenopausal women with osteoporosis at high risk of fracture.

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

Entera Bio Ltd. announced that its CEO, Miranda Toledano, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The company, a leader in oral peptide development, will also hold 1x1 meetings during the conference, which will be webcast live. Entera Bio focuses on developing oral peptide and protein replacement therapies, with its most advanced candidate, EB613, for osteoporosis.

Entera Bio CEO to speak at Canaccord Genuity Growth Conference on Aug 12, 2026

Entera Bio Ltd., a clinical-stage company specializing in oral peptide therapies, announced that CEO Miranda Toledano will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. This event, held in Boston and streamed online, will provide insights into Entera's progress, including its lead osteoporosis treatment EB613, which is currently in Phase 2 trials. The announcement highlights the company's commitment to advancing its innovative pipeline.

Entera Bio CEO's Aug. 12 Fireside Chat Will Stream Online

Entera Bio (NASDAQ: ENTX) announced that CEO Miranda Toledano will participate in a fireside chat and 1x1 meetings at the Canaccord Genuity 46th Annual Growth Conference. The fireside chat is scheduled for August 12, 2026, at 1:00 p.m. Eastern Time in Boston, and a live webcast will be available with a replay for 365 days. The company, a clinical-stage firm focused on oral peptide and protein replacement therapies, will highlight its lead osteoporosis candidate EB613 and other pipeline programs.

Entera Bio Ltd (ENTX) Institutional Confidence

Entera Bio Ltd (ENTX) has an institutional shareholding score of 3.00, placing it 192nd out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 17.10%, a 24.51% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.02% of outstanding shares.

Entera Bio CEO's Aug. 12 Fireside Chat Will Stream Online

Entera Bio (NASDAQ: ENTX) announced that CEO Miranda Toledano will participate in a fireside chat and 1x1 meetings at the Canaccord Genuity 46th Annual Growth Conference. The fireside chat is scheduled for August 12, 2026, at 1:00 p.m. Eastern Time in Boston, and a live webcast will be available with a replay for 365 days. The company, a clinical-stage firm focused on oral peptide and protein replacement therapies, will highlight its lead osteoporosis candidate EB613 and other pipeline programs.

Entera Bio Ltd (ENTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Entera Bio Ltd (ENTX), detailing its current price momentum score, support and resistance levels, and the status of common technical indicators and moving averages. The stock is currently trading between a resistance level of $4.24 and a support level of $1.61, suggesting suitability for range-bound swing trading. Indicators like MACD, RSI, and StochRSI, along with various moving averages, are presented with their respective buy, sell, or neutral signals.

Why the World's Leading Healthcare Funds All Wanted a Piece of Entera Bio (NASDAQ: ENTX)

Entera Bio (NASDAQ: ENTX) recently announced an oversubscribed $275 million private placement, attracting investments from leading healthcare funds like BVF Partners, Longitude Capital, and Vivo Capital. This significant capital raise for a company with a market capitalization under $60 million at the start of the year highlights strong institutional confidence in Entera Bio's lead drug candidate, EB613, which is heading into Phase 3 trials for osteoporosis. The financing, priced at market without significant discounts or warrants, further signals the investors' belief in the substantial asymmetric upside and blockbuster potential of EB613, a first-in-class oral anabolic for osteoporosis poised to address a large and underserved market.

Entera Bio Ltd. (ENTX) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live stock quotes and charts for Entera Bio Ltd. (ENTX) on NASDAQ, showing a current price of $3.15, up 5.00%. It also notes that there are currently no analyst ratings or earnings information available for the company. The site prominently features calls to action for trading education and free trade alerts.

Entera Bio Ltd (ENTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

Entera Bio Ltd. announced that it expects to receive $274.999977 million in funding from a group of investors

Entera Bio Ltd. has secured approximately $275 million in funding through an oversubscribed private placement. The financing involved issuing ordinary shares and pre-funded warrants to a group of investors, with BVF Partners L.P. leading the placement and participation from several new investors including Longitude Capital and Vivo Capital. This funding is intended to support the company's initiatives in developing orally delivered large molecule therapeutics.

Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement

Entera Bio Ltd. has announced an oversubscribed private placement expected to raise approximately $275 million. This funding, led by existing investor BVF Partners L.P. and including new investors, will extend the company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, their oral PTH(1-34) peptide tablet for osteoporosis, and advance other pipeline candidates.

Entera Bio Ltd (ENTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on Entera Bio Ltd (ENTX)'s dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years, showing "No Data" for dividend dates. The article also presents current stock performance data, including its market cap loss.

Entera Bio Ltd (ENTX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Entera Bio Ltd (ENTX), listing both major institutional and individual shareholders, along with their respective proportions. It also includes a historical overview of institutional shareholdings and recent shareholder activity, such as changes in holdings by key investors. The data provides insights into the ownership landscape of the company.